Multiple sclerosis (MS) is central nervous system (CNS) based disease. It is a chronic inflammatory demyelinating disease [1]. The main causes for MS are genetic and environmental factors. It is a disease of young people (median age of onset is around 28 years) but is lifetime and is often disabling; 50% of patients need a cane to walk 15 years after disease onset; and Worldwide more than 2.5 Million persons are affected.

CNS myelination is a well-known biological phenomenon related to increase in action potential conduction speed and synaptic integration. Demyelination or abnormal myelination has been related to seizures and epilepsy either in patients or animal models. Although its role in fastening action potential propagation has been confirmed, few additional biological functions of CNS myelin has been described.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that effects more than 1.3 million people in the United States. RA is an expensive disease that negatively impacts the patient’s quality of life. Inflammation of the synovial joints and destruction of articular cartilage and bones caused by RA can affect a patient’s ability to perform commonplace activities.

Rheumatoid arthritis (RA) is a chronic disease of yet unknown etiology causing joint tenderness, swelling, destruction and premature death. Extraarticular manifestations such as cervical spine involvement, bursitis, tendovaginitis, rheumatoid nodules, rheumatoid vasculitis, pulmonary fibrosis, and accelerated atherosclerosis - to name a few – may occur.

Rheumatoid arthritis (RA) is a chronic, autoimmune disease that is associated with local and systemic inflammation, resulting in chronic pain and physical function limitations that may negatively impact quality of life (QOL). Despite advances in pharmacological therapies, currently available treatment options may be associated with adverse events and come at a high price tag.